AstraZeneca

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab (öffnet in neuem Tab)

  Oncodaily · 02.10.2026

• AstraZeneca, Daiichi Partner With Summit on Cancer-Drug Trials (öffnet in neuem Tab)

  Bloomberg.com · 02.10.2026

• AstraZeneca, Daiichi Sankyo and Summit Therapeutics Plan Datroway–Ivonescimab Combination Trials (öffnet in neuem Tab)

  Yahoo Finance UK · 02.10.2026

• AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (öffnet in neuem Tab)

  Reuters · 02.10.2026

• AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo (öffnet in neuem Tab)

  Seeking Alpha · 02.10.2026

• AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types (öffnet in neuem Tab)

  AstraZeneca · 02.10.2026

• Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (öffnet in neuem Tab)

  Business Wire · 02.10.2026

• Hong Kong needs new funding model to attract global drug makers: AstraZeneca (öffnet in neuem Tab)

  South China Morning Post · 01.10.2026

• 700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 (öffnet in neuem Tab)

  Yahoo Finance · 30.09.2026

• AstraZeneca slips Wednesday, underperforms market (öffnet in neuem Tab)

  MarketWatch · 30.09.2026

• AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (öffnet in neuem Tab)

  24/7 Wall St. · 30.09.2026

• AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (öffnet in neuem Tab)

  24/7 Wall St. · 30.09.2026

• Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge (öffnet in neuem Tab)

  Fierce Pharma · 30.09.2026

• AstraZeneca Dealt Latest Loss in Arkansas Drug Discount Case (öffnet in neuem Tab)

  Bloomberg Law News · 30.09.2026

• AstraZeneca commits $2bn to advance ADC combination medicines for cancer (öffnet in neuem Tab)

  European Pharmaceutical Review · 30.09.2026

• AstraZeneca (LSE:AZN) Wins FDA Priority Review For IMFINZI In Bladder Cancer (öffnet in neuem Tab)

  Simply Wall St. · 30.09.2026

• AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll (öffnet in neuem Tab)

  BioSpace · 30.09.2026

• Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing? (öffnet in neuem Tab)

  Simply Wall St. · 30.09.2026

• AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment (öffnet in neuem Tab)

  european-biotechnology.com · 30.09.2026

• AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up (öffnet in neuem Tab)

  Reuters · 30.09.2026

• AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination (öffnet in neuem Tab)

  Reuters · 30.09.2026

• Vital Signs: AstraZeneca's $2B seat at Summit's table (öffnet in neuem Tab)

  FirstWord Pharma · 30.09.2026

• Physician Views Results: European pulmonologists see AstraZeneca's Trixeo as another option in asthma (öffnet in neuem Tab)

  FirstWord Pharma · 29.09.2026

• Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note (öffnet in neuem Tab)

  Zacks · 29.09.2026

• AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck (öffnet in neuem Tab)

  Investor's Business Daily · 29.09.2026

• AstraZeneca Pays $2 Billion To Take On Pfizer, Merck, Bristol (öffnet in neuem Tab)

  Investor's Business Daily · 29.09.2026

• A $2 Billion Reason Why AstraZeneca Stock Is Down Today (öffnet in neuem Tab)

  Barchart.com · 29.09.2026

• AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug (öffnet in neuem Tab)

  MedCity News · 29.09.2026

• AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says (öffnet in neuem Tab)

  MT Newswires · 29.09.2026

• Summit Shares Jump on $2B Strategic Investment From AstraZeneca (öffnet in neuem Tab)

  Zacks Investment Research · 29.09.2026